First-line HCVAD + Ponatinib Appears Superior to HCVAD + Dasatinib in Ph+ ALL

Slideset - This propensity score analysis comparing 2 phase II studies shows improved EFS and OS with addition of ponatinib vs dasatinib to standard HCVAD chemotherapy in newly diagnosed Ph+ ALL.
Source: Clinical Care Options Leukemia - Category: Hematology Source Type: research